JP2016501852A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501852A5
JP2016501852A5 JP2015543216A JP2015543216A JP2016501852A5 JP 2016501852 A5 JP2016501852 A5 JP 2016501852A5 JP 2015543216 A JP2015543216 A JP 2015543216A JP 2015543216 A JP2015543216 A JP 2015543216A JP 2016501852 A5 JP2016501852 A5 JP 2016501852A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cellular
particulate
fecal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015543216A
Other languages
English (en)
Other versions
JP2016501852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2013/001362 external-priority patent/WO2014078911A1/en
Publication of JP2016501852A publication Critical patent/JP2016501852A/ja
Publication of JP2016501852A5 publication Critical patent/JP2016501852A5/ja
Pending legal-status Critical Current

Links

Claims (15)

  1. 精製された糞便微生物叢および1つまたは複数の非-細胞性であって非-粒子状の糞便成分の組合せから必須になる再構成された糞便フローラを含む、医薬組成物。
  2. 1つまたは複数の非-細胞性であって非-粒子状の糞便成分が追加された、精製された糞便微生物叢を含む、医薬組成物。
  3. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、合成分子、糞便微生物によって産生される生物学的に活性な分子、またはこれら両方を含む、請求項1または2に記載の医薬組成物。
  4. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、生物学的に活性なタンパク質もしくはペプチド、微量栄養素、脂質、糖、低分子の炭水化物、微量元素、無機塩、灰分、粘液、アミノ酸、栄養素、ビタミン、ミネラルまたはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
  5. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、バクテリオシン、ランバイオティクスおよびラクチシンからなる群から選択される1つまたは複数の生物学的に活性な分子を含む、請求項1または2に記載の医薬組成物。
  6. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、コリシン、トロウドゥリキシン、プタインディシン、ミクロシンおよびサブチロシンAからなる群から選択される1つまたは複数のバクテリオシンを含む、請求項1または2に記載の医薬組成物。
  7. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、ツリシン、ナイシン、スブチリン、エピデルミン、ミュータシン、メルサシジン、アクタガルジンおよびシンナマイシンからなる群から選択される1つまたは複数のランバイオティクスを含む、請求項1または2に記載の医薬組成物。
  8. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、抗-胞子化合物、抗菌化合物、抗-炎症性化合物、またはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
  9. 前記1つまたは複数の非-細胞性であって非-粒子状の糞便成分が、インターロイキン、サイトカイン、ロイコトリエン、エイコサノイド、またはそれらの任意の組合せを含む、請求項1または2に記載の医薬組成物。
  10. 前記精製された糞便微生物叢が、約0.1mmより大きなサイズを有する粒子を含まない、請求項1または2に記載の医薬組成物。
  11. バイオフィルム崩壊剤を更に含むか、またはバイオフィルム崩壊剤と併せて使用される、請求項1または2に記載の医薬組成物。
  12. 前記バイオフィルム崩壊剤が、デオキシリボヌクレアーゼ(DNアーゼ)、N-アセチルシステイン、アルギン酸リアーゼ、グリコシドヒドロラーゼディスパーシンB、クオラムセンシング阻害剤、リボ核酸III阻害ペプチド、サルバドラ・ペルシカ抽出物、コンピテンス刺激ペプチド、パツリン、ペニシリン酸、カテリシジン由来ペプチド、小溶解性ペプチド、PTP-7、酸化窒素、ネオエマルジョン、オゾン、溶解性バクテリオファージ、ラクトフェリン、キシリトールヒドロゲル、合成鉄キレート剤、クルクミン、銀ナノ粒子、アセチル-11-ケト-β-ボスウェル酸(AKBA)、シネファンギン、S-アデノシルメチオニン、S-アデノシル-ホモシステイン、デリシアフラノン、およびN-スルホニルホモセリンラクトンからなる群から選択される、1つまたは複数の酵素を含む、請求項11に記載の医薬組成物。
  13. 遅延性または徐放性の腸溶性放出用に配合された、請求項1または2に記載の医薬組成物。
  14. 必要とする対象における、腸管機能不全成分を有する状態の治療または予防のための、請求項1から13のいずれか一項に記載の医薬組成物。
  15. 前記状態が、便秘、腹痛、下痢、クローン病、毒、毒素、感染、毒素媒介性旅行者下痢症、クロストリジウム、C.パーフリンジェンス・ウェルチ、C.ディフィシル感染、またはクロストリジウム感染に関連した偽膜性大腸炎、脊椎関節症、脊椎関節炎、仙腸関節炎、腎炎症候群、炎症性状態、自己免疫状態、ループス、過敏性腸症候群(IBS)、結腸炎、潰瘍性結腸炎、自閉症、神経変性疾患、筋委縮性側索硬化症(ALS)、多発性硬化症(MS)、パーキンソン病(PD)、ミオクローヌスジストニア、シュタイネルト病、近位型筋強直性ミオパシー、関節リウマチ(RA)、若年性特発性関節炎(HA)、慢性疲労症候群、良性筋痛性脳脊髄炎、慢性疲労免疫機能障害症候群、慢性感染性単核球症、流行性筋痛性脳脊髄炎、肥満、低血糖症、前糖尿病性症候群、I型糖尿病、II型糖尿病、特発性血小板減少性紫斑病(ITP)、急性または慢性アレルギー反応、蕁麻疹、発疹、皮膚掻痒、慢性皮膚掻痒、不眠症、慢性不眠症、けいれん大発作、けいれん小発作、口臭、肝腎症候群、憩室炎、再発性憩室炎、アトピー性状態、喘息、注意欠陥障害(ADD)、強迫性障害(OCD)、鬱病、統合失調症および気分障害からなる群から選択される、請求項14に記載の医薬組成物。
JP2015543216A 2012-11-26 2013-11-26 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法 Pending JP2016501852A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729994P 2012-11-26 2012-11-26
US61/729,994 2012-11-26
PCT/AU2013/001362 WO2014078911A1 (en) 2012-11-26 2013-11-26 Compositions for the restoration of a fecal microbiota and methods for making and using them

Publications (2)

Publication Number Publication Date
JP2016501852A JP2016501852A (ja) 2016-01-21
JP2016501852A5 true JP2016501852A5 (ja) 2017-05-18

Family

ID=50775319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543216A Pending JP2016501852A (ja) 2012-11-26 2013-11-26 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法

Country Status (10)

Country Link
US (2) US20150297642A1 (ja)
EP (1) EP2922555A4 (ja)
JP (1) JP2016501852A (ja)
KR (1) KR20150103012A (ja)
CN (1) CN104918624A (ja)
AU (2) AU2013350328A1 (ja)
BR (1) BR112015012123A8 (ja)
CA (1) CA2896795A1 (ja)
IL (1) IL238993A0 (ja)
WO (1) WO2014078911A1 (ja)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2008143889A1 (en) 2007-05-14 2008-11-27 Research Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
US9629881B2 (en) 2010-02-01 2017-04-25 Rebiotix, Inc. Bacteriotherapy for clostridium difficile colitis
WO2011151941A1 (ja) 2010-06-04 2011-12-08 国立大学法人東京大学 制御性t細胞の増殖または集積を誘導する作用を有する組成物
US9308226B2 (en) 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9968638B2 (en) 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
EP2785828B1 (en) * 2011-12-01 2020-04-08 The University of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10383901B2 (en) 2013-06-05 2019-08-20 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9694039B2 (en) 2013-06-05 2017-07-04 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
KR102099503B1 (ko) 2013-06-05 2020-04-09 리바이오틱스, 인코퍼레이티드 미생물상 복원 요법(mrt) 조성물
US9511100B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9782445B2 (en) 2013-06-05 2017-10-10 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
US9511099B2 (en) 2013-06-05 2016-12-06 Rebiotix, Inc. Microbiota restoration therapy (MRT), compositions and methods of manufacture
GB2529893A (en) * 2014-09-08 2016-03-09 Geotechniquesres Ltd Apparatus and method for separating pollen and optionally microbiota from honey
MA41020A (fr) 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
KR20220151045A (ko) 2014-12-23 2022-11-11 4디 파마 리서치 리미티드 면역 조정
SE1550189A1 (en) * 2015-02-19 2016-08-20 Achim Biotherapeutics Ab Therapeutic and prophylactic composition produced by microbiota
WO2016172380A1 (en) * 2015-04-21 2016-10-27 Epibiome, Inc. Compositions and methods for increasing the susceptibility of bacteria to antibiotics
US12050161B2 (en) 2015-04-24 2024-07-30 Maat Pharma Microorganism sampling method, microorganism sampling device and sampling kit comprising such a sampling device
FR3035328B1 (fr) 2015-04-24 2019-08-23 Maat Pharma Procede de preparation d'un echantillon de microbiote fecal
FR3035317B1 (fr) 2015-04-24 2019-06-14 Maat Pharma Dispositif de prelevement de micro-organismes, kit de prelevement comprenant un tel dispositif et procede de prelevement mettant en œuvre un tel dispositif
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN114159476A (zh) 2015-05-14 2022-03-11 克雷斯顿沃控股公司 用于粪便菌群移植的组合物以及用于制备和使用它们的方法和用于递送它们的装置
NZ776366A (en) * 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
US10828340B2 (en) 2015-06-09 2020-11-10 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10905726B2 (en) 2015-06-09 2021-02-02 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10799539B2 (en) 2015-06-09 2020-10-13 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
US10226431B2 (en) 2015-06-09 2019-03-12 Rebiotix, Inc. Microbiota restoration therapy (MRT) compositions and methods of manufacture
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PT3240554T (pt) 2015-06-15 2019-11-04 4D Pharma Res Ltd Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6426264B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
JP6439037B2 (ja) 2015-06-15 2018-12-19 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
CN105193856A (zh) * 2015-09-25 2015-12-30 南昌大学 一种人工培养粪便菌群移植在肠道疾病治疗中的应用
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN112569262A (zh) 2015-11-20 2021-03-30 4D制药研究有限公司 包含细菌菌株的组合物
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CN106811425B (zh) * 2015-11-27 2020-10-09 重庆北芝堂生物科技有限公司 一种从人体粪便中分离肠道菌群的方法
FR3045383B1 (fr) 2015-12-18 2019-06-14 Maat Pharma Procede de lyophilisation d'un echantillon de microbiote fecal
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
SG11201807811RA (en) * 2016-03-11 2018-10-30 Evolve Biosystems Inc Food compositions for weaning
WO2017203533A1 (en) * 2016-05-25 2017-11-30 Mybiotics Pharma Ltd. Composition and methods for microbiota therapy
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TWI802545B (zh) 2016-07-13 2023-05-21 英商4D製藥有限公司 包含細菌菌株之組合物
US20180030403A1 (en) 2016-07-28 2018-02-01 Bobban Subhadra Devices, systems and methods for the production of humanized gut commensal microbiota
US20180036352A1 (en) * 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
AU2017327369A1 (en) 2016-09-13 2019-05-02 Allergan, Inc. Stabilized non-protein Clostridial toxin compositions
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071536A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating primary sclerosing cholangitis and related disorders
WO2018071532A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating chronic fatigue syndrome and related disorders
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
WO2018071534A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating irritable bowel syndrome and related disorders
WO2018081196A1 (en) * 2016-10-31 2018-05-03 Kimberly-Clark Worldwide, Inc. Method for archiving a microbiome
IT201600122310A1 (it) 2016-12-01 2018-06-01 Sofar Spa Composizione per uso nella terapia di alterazioni dell'intestino
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
FR3062063B1 (fr) * 2017-01-26 2019-04-19 Centre National De La Recherche Scientifique Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CN110831606A (zh) 2017-04-05 2020-02-21 克雷斯顿沃控股公司 治疗帕金森氏病(pd)和相关疾病的组合物和方法
CN107126445A (zh) * 2017-04-20 2017-09-05 江南大学 粪菌移植在治疗帕金森病方面的应用
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US11890306B2 (en) 2017-05-26 2024-02-06 Finch Therapeutics Holdings Llc Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same
CN108947097B (zh) * 2017-05-27 2021-10-22 宝山钢铁股份有限公司 一种平整液废水臭氧生化耦合的处理方法和装置
PT3600364T (pt) 2017-06-14 2020-10-19 4D Pharma Res Ltd Composições compreendendo uma estirpe bacteriana do género megasphera e suas utilizações
SI3638271T1 (sl) 2017-06-14 2021-01-29 4D Pharma Research Limited Sestavki, ki vsebujejo bakterijske seve
PL3600363T3 (pl) 2017-06-14 2021-06-14 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
AU2018253466B2 (en) * 2017-07-17 2019-03-28 smartDNA Pty Ltd Method of diagnosing a dysbiosis
JP2020530494A (ja) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 健康な腸バリアを維持及び回復するための組成物及び方法
EP3485879A1 (en) * 2017-11-17 2019-05-22 Maat Pharma Pharmaceutical oral formulation comrpsing bacteria
CN112203669A (zh) 2018-02-23 2021-01-08 克雷斯顿沃控股公司 微生物组相关的免疫疗法
WO2019213595A1 (en) * 2018-05-04 2019-11-07 Ferring B.V. Microbiota restoration therapy (mrt) compositions and methods of manufacture
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
US11859214B1 (en) 2018-08-17 2024-01-02 The Government Of The United States, As Represented By The Secretary Of The Army Automated system for simulating the human lower gastrointestinal tract
CN109010380A (zh) * 2018-08-21 2018-12-18 卓源健康科技有限公司 一种粪菌移植临床治疗中的肠道菌群制剂的工艺
WO2020069280A1 (en) 2018-09-27 2020-04-02 Crestovo Holdings Llc Compositions and methods for treating epilepsy and related disorders
WO2020086413A1 (en) * 2018-10-26 2020-04-30 Locus Oil Ip Company, Llc Personalized system for restoring the gastrointestinal tract microbiome
CA3116775A1 (en) * 2018-11-09 2020-05-14 The Brigham And Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of dysbiosis
US11058634B2 (en) 2018-11-19 2021-07-13 Steven J. Edwards Adherent oral pharmabiotic delivery strip
KR20220000398A (ko) 2019-04-12 2022-01-03 로커스 아이피 컴퍼니 엘엘씨 향상된 탄소 격리 및 가축 생산 온실 가스 배출 감소를 위한 목초지 처리
WO2020237323A1 (en) * 2019-05-31 2020-12-03 Borody Thomas J Devices, compositions and methods for colonic microbiome engraftment
US12053447B2 (en) 2019-06-25 2024-08-06 NuBioPharma, LLC Oral solution and powder to liquid compositions of balsalazide
EP3996727A4 (en) * 2019-07-11 2023-03-15 Milis, Antony PROCEDURE FOR PREPARING INTESTINAL MUCOA FOR IMPROVING MICROBIAL COLONIZATION
WO2021016081A1 (en) 2019-07-19 2021-01-28 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
EP4007540A4 (en) * 2019-08-02 2023-08-16 Thomas Julius Borody COLON TREATMENT METHODS AND APPARATUS
US20220322707A1 (en) * 2019-08-14 2022-10-13 Locus Ip Company, Llc Drinkable Supplement Composition for Improved Health and Hydration
JP2022547330A (ja) 2019-09-13 2022-11-11 フィンチ セラピューティクス ホールディングス エルエルシー 自閉症スペクトラム障害を治療するための組成物および方法
JP2022552005A (ja) 2019-10-18 2022-12-14 フィンチ セラピューティクス ホールディングス エルエルシー 細菌代謝産物を対象に送達するための組成物および方法
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
EP4085916A4 (en) 2019-11-26 2024-03-27 Tokyo Metropolitan Hospital Organization PROPHYLACTIC OR THERAPEUTIC COMPOSITION FOR GRAFT VERSUS HOST DISEASE
WO2021115415A1 (en) * 2019-12-11 2021-06-17 Microbiota I - Center (Magic) Limited Methods for treating bacterial infections
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142353A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatitis b (hbv) and hepatitis d (hdv)
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
CN111249314B (zh) * 2020-03-03 2022-03-29 深圳未知君生物科技有限公司 人体共生菌群在提高肿瘤免疫治疗应答中的作用
EP4125440A1 (en) * 2020-03-31 2023-02-08 Biomuse Ltd. Bacteria for the prevention and treatment of smoke-induced lung damage
WO2021202806A1 (en) 2020-03-31 2021-10-07 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
CN111544550B (zh) * 2020-06-19 2021-11-09 南京法迈特科技发展有限公司 中药配方菌群胶囊及制备方法和在制备治疗2型糖尿病的药物中的应用
WO2022178294A1 (en) 2021-02-19 2022-08-25 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
EP4098268A1 (en) * 2021-06-01 2022-12-07 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing lyophilized fecal matter filtrate
ES2933976B2 (es) * 2021-08-11 2024-05-08 Fundacio Inst Dinvestigacio Biomedica De Girona Dr Josep Trueta Idibgi Bacteriofago para uso terapeutico
CN114027479A (zh) * 2021-11-18 2022-02-11 武汉自然萃创新科技有限公司 一种微胶囊化益生菌蜂蜜的制备方法
EP4183403A1 (en) * 2021-11-19 2023-05-24 Lietuvos Sveikatos Mokslu Universitetas Modification of fecal microbiota with capsules containing gram-positive bacteria
CN114350520A (zh) * 2022-01-19 2022-04-15 厦门承葛生物科技有限公司 一种肠道菌群的过滤提取方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170617A1 (en) * 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
CN1737108A (zh) * 2004-08-18 2006-02-22 王健 一种从人体排泄物中分离益生菌的方法
US9320795B2 (en) * 2007-12-13 2016-04-26 Zoctis Server LLC Bacteriophage preparations and methods of use thereof
GB0916335D0 (en) * 2009-09-17 2009-10-28 Martin W J Medicaments
US9308226B2 (en) * 2010-08-04 2016-04-12 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
US9968638B2 (en) * 2011-03-09 2018-05-15 Regents Of The University Of Minnesota Compositions and methods for transplantation of colon microbiota
CA2848757C (en) * 2011-09-14 2021-11-09 University Of Guelph Methods to culture human gastrointestinal microorganisms
WO2013090825A1 (en) * 2011-12-15 2013-06-20 Pureflora, Inc. Device for the collection, refinement, and administration of gastrointestinal microflora

Similar Documents

Publication Publication Date Title
JP2016501852A5 (ja)
Allain et al. Interactions of Giardia sp. with the intestinal barrier: Epithelium, mucus, and microbiota
Meade et al. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile?
Ilinskaya et al. Secretome of intestinal Bacilli: a natural guard against pathologies
Leshem et al. Immune-microbiota interplay and colonization resistance in infection
Pace et al. Probiotics in digestive diseases: focus on Lactobacillus GG.
Yang et al. Bile acid–gut microbiota axis in inflammatory bowel disease: from bench to bedside
Rea et al. Gut solutions to a gut problem: bacteriocins, probiotics and bacteriophage for control of Clostridium difficile infection
Singh et al. Identification, purification and characterization of laterosporulin, a novel bacteriocin produced by Brevibacillus sp. strain GI-9
Saraoui et al. Inhibition mechanism of Listeria monocytogenes by a bioprotective bacteria Lactococcus piscium CNCM I-4031
Li et al. Antimicrobial resistance of Campylobacter species isolated from broilers in live bird markets in Shanghai, China
Patenge et al. Inhibition of growth and gene expression by PNA-peptide conjugates in Streptococcus pyogenes
Yang et al. Non-antibiotic therapy for Clostridioides difficile infection: A review
Egan et al. Bacteriocins: antibiotics in the age of the microbiome
Xu et al. Isolation and characterization of cyclic lipopeptides with broad-spectrum antimicrobial activity from Bacillus siamensis JFL15
BRPI1011277B8 (pt) produto de bacteriocina lactobacillus pentosus, alimento e composições farmacêuticas contendo o mesmo e uso do mesmo
Kuniyoshi et al. An oxidation resistant pediocin PA-1 derivative and penocin A display effective anti-Listeria activity in a model human gut environment
Mukherjee et al. Bacteriocin-producing strains of Lactobacillus plantarum inhibit adhesion of Staphylococcus aureus to extracellular matrix: quantitative insight and implications in antibacterial therapy
Cirkovic et al. Licheniocin 50.2 and bacteriocins from Lactococcus lactis subsp. lactis biovar. diacetylactis BGBU1-4 inhibit biofilms of coagulase negative Staphylococci and Listeria monocytogenes clinical isolates
Dare et al. LysPGS formation in Listeria monocytogenes has broad roles in maintaining membrane integrity beyond antimicrobial peptide resistance
Pantic et al. Effects of tigerinin peptides on cytokine production by mouse peritoneal macrophages and spleen cells and by human peripheral blood mononuclear cells
Burkovski Corynebacterium pseudodiphtheriticum: Putative probiotic, opportunistic infector, emerging pathogen
Yu et al. Biosynthetic microcin J25 exerts strong antibacterial, anti-inflammatory activities, low cytotoxicity without increasing drug-resistance to bacteria target
Sivaraj et al. Potential applications of lactic acid bacteria and bacteriocins in anti-mycobacterial therapy
Yang et al. Screening, probiotic properties, and inhibition mechanism of a Lactobacillus antagonistic to Listeria monocytogenes